---
title: "Page 1"
canonical: "/page-1-nfcqrx"
published: 2026-09-22
---

# Page 1

## Section · 1 Hero

NCODA IMMUNOTHERAPY RESOURCES

Harnessing the immune system,implemented with confidence.

Practice-ready tools for the oncology care team delivering T-cell–redirecting therapies. Choose a hub below to explore curated clinical education, patient resources, and real-world implementation support.

TUMOR CELL

T-CELL

## Section · 2 Hub cards

NOW LIVE

COMING SOON

Bispecific T-Cell Engager Hub

CAR-T Cell Therapy Hub

HUB 01

HUB 02

Bispecific T-Cell Engager Hub

CAR-T Cell Therapy Hub

Support the safe, effective implementation of bispecific T-cell engager (BTCE) therapies across a range of clinical settings — from step-up dosing to CRS and ICANS management.

Curated, practice-ready resources supporting the safe, effective implementation of CAR-T cell therapy — across every stage of the patient journey, from referral and apheresis to infusion and monitoring.

- Clinical education & microlearning videos
- Treatment discussion guides & PQIs
- Patient education sheets & treatment calendars
- EMR toolkits & implementation resources

- Foundations clinical education
- “Up Close” agent-specific resources for FDA-approved CAR-T therapies
- Example SOPs & real-world practice documents
- Implementation toolkits & recommended reading

**Explore the Bispecific Hub →**

**Preview the CAR-T Hub →**

## Section · 3 At a Glance

AT A GLANCE

Two approaches. One goal.

Both therapy classes redirect a patient’s T cells against cancer — but they differ in how they’re made, delivered, and managed.

BISPECIFIC T-CELL ENGAGERS

CAR-T CELL THERAPY

How it works

An antibody that binds a T cell and a tumor-cell target at the same time, bringing them together.

The patient’s own T cells are genetically engineered to express a chimeric antigen receptor that recognizes the tumor.

Product

Off-the-shelf; available without cell manufacturing.

Personalized; requires apheresis and a manufacturing period.

Administration

Repeated dosing, typically starting with a step-up schedule.

Typically a single infusion following lymphodepleting chemotherapy.

Key safety focus

CRS and ICANS, most often during step-up dosing; infection risk.

CRS and ICANS after infusion; prolonged monitoring and infection risk.

Care setting

Hospital and increasingly community practice settings.

Certified treatment centers with coordinated referral pathways.

General educational overview. Refer to each product’s prescribing information and institutional protocols.

## Section · 4 Inside the Hubs

INSIDE THE HUBS

Built for every member of the care team

Resources developed with oncology practitioners to move immunotherapy from guideline to real-world practice.

Clinical Education

Patient Resources

SOPs & Toolkits

Discussion Guides

Microlearning videos, podcasts, and foundational overviews.

Education sheets and treatment calendars to support the patient journey.

Example SOPs, EMR toolkits, and workflow documents from real practices.

Treatment discussion guides and PQIs for pharmacists, nurses, and prescribers.

## Section · 5 Closing CTA

Advancing immunotherapy, together.

**Bispecific T-Cell Engager Hub**

→

**CAR-T Cell Therapy Hub**

Start with the hub that fits your practice today — and check back as NCODA continues to expand its immunotherapy resources.

→